← All trials
NCT01899859
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2013
- Primary completion
- Feb 1, 2015
- Completion date
- Feb 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 31
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Galectin Therapeutics Inc.Lead sponsor
- Emory UniversityOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- Virginia Commonwealth UniversityOverall official - principal investigator
- St. Louis UniversityOverall official - principal investigator
- United States ArmyOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.